Sanofi Garners Highest Physician Interest in Asthma Pipeline, Despite GSK’s Later-Stage Asset, According to Spherix Global Insights

EXTON, PA, May 13, 2025 (GLOBE NEWSWIRE) — Although no new biologics for asthma have been approved since the 2021 launch of Tezspire (Amgen/AstraZeneca), recent insights from Spherix Global Insights point to a market primed for innovation.  The latest data uncovers persistent treatment gaps and highlights the pipeline assets gaining meaningful traction with prescribers—signaling potential shifts in a recently stable landscape. 

According to the recently published Market Dynamix™: Asthma (US) 2025 study, U.S. allergists (n=84) indicate that approximately half of their adult patients with moderate-to-severe asthma are currently treated with biologics, while pulmonologists (n=22) report slightly lower biologic adoption use among their patient populations. Prescribers currently state that Sanofi/Regeneron’s Dupixent continues to lead current adult biologic brand share. Despite the widespread use of biologics for the treatment of asthma, Tezspire is the only brand demonstrating notable growth potential, driven by a significant pool of eligible, yet untreated, patients.. Additional findings suggest that current treatment options haven’t fully addressed the unmet treatment need for patients with severe asthma, underscoring the opportunity for more effective treatment options. 

This persistent unmet need for more effective therapies in severe asthma is fueling strong interest in the emerging pipeline. A robust array of agents is advancing through Phase 2 and 3 developments, many with novel mechanisms of action that signal potential differentiation. Notable examples include Connect Biopharma’s CBP-201 (IL-4 receptor alpha subunit antagonist) and Fountain Biopharma’s FB704A (IL-6 inhibitor). Among the candidates generating the most enthusiasm are Sanofi’s assets—amlitelimab (BTK inhibitor), lunsekimig (IL-13xTSLP Nanobody VHH), and oral rilzabrutinib (OX40L mAb)—which physicians recognize as having the strongest potential to surpass current treatment standards. 

Despite its profile as a long-acting IL-5 receptor antagonist with convenient semiannual dosing, GSK’s depemokimab, the most advanced asthma pipeline asset, has generated relatively limited enthusiasm among prescribers. While allergists show increased interest in prescribing depemokimab in a first-line setting upon reviewing its promising phase 3 results from September 2024, concerns about reduced office visits potentially affecting adherence also emerge. One physician commented, “I don’t like a biologic agent lasting six months as these patients need more frequent visits and are not likely to return until they have an exacerbation.”  

While physician enthusiasm for depemokimab is more tempered compared to other pipeline agents, the therapy may still be well-positioned to meet critical needs in severe asthma management. As prescribers continue to seek novel solutions, depemokimab’s recent clinical data and pending indication suggest potential value in this space. In fact, Spherix Global Insights’ derived importance analysis underscores that to shape brand perception, new treatments must deliver more than just exacerbation reduction. Attributes such as sustained response between doses and favorable tolerability represent underleveraged opportunities for meaningful differentiation. 

As manufacturers prepare for potential launch, these findings reaffirm the ongoing unmet needs among patients with severe asthma, despite existing treatment options. Building awareness and differentiating pipeline assets will be essential to stand out in a crowded landscape.  

Amidst the ongoing transformation of the asthma market and the influx of innovative therapies, expert guidance is essential. Spherix Global Insights, through its commitment to rigorous, independent research, offers biotech and pharmaceutical companies strategic insights. This expertise enables organizations to navigate the competitive landscape confidently, precisely target patient populations, and ultimately elevate the standard of care in asthma management. 

Market Dynamix™ is an independent service providing analysis of markets anticipated to experience a paradigm shift within the next three to five years. Insights highlight market size, current treatment approaches, unmet needs, and expert opinions on the likely disruption introduced by pipeline agents.

About Spherix Global Insights  

Spherix is a leading independent market intelligence and advisory firm that delivers commercial value to the global life sciences industry, across the brand lifecycle.  

The seasoned team of Spherix experts provides an unbiased and holistic view of the landscape within rapidly evolving specialty markets, including dermatology, gastroenterology, rheumatology, nephrology, neurology, ophthalmology, and hematology. Spherix clients stay ahead of the curve with the perspective of the extensive Spherix Physician Community.  

As a trusted advisor and industry thought leader, Spherix’s unparalleled market insights and advisory services empower clients to make better decisions and unlock opportunities for growth.  

To learn more about Spherix Global Insights, visit spherixglobalinsights.com or connect through LinkedIn.   

For more details on Spherix’s primary market research reports and interactive dashboard offerings, visit or register here: https://clientportal.spherixglobalinsights.com

Spherix Global Insights Contacts   

Andy Stankus, Dermatology Franchise Head  

[email protected]

NOTICE: All company, brand or product names in this press release are trademarks of their respective holders. The findings and opinions expressed within are based on Spherix Global Insight’s analysis and do not imply a relationship with or endorsement of the companies or brands mentioned in this press release.

Wall St Business News, Latest and Up-to-date Business Stories from Newsmakers of Tomorrow